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challenged by the weak protective activity of mito- hepatectomy, albeit both processes are governed by
integration of activities of TNF-Rs, JNK, and NF-κB.chondrial Mn-SOD (Sakon et al., 2003; Pham et al.,
2004). Putative extramitochondrial sources of TNF-R1- Identifying the mechanisms responsible for ROS-medi-
ated JNK induction and NF-κB-dependent protection ininduced ROS have in fact been identified. Ultimately,
identifying the origin of ROS will require employing ge- patho-physiological contexts such as these represents
a major challenge yet holds great promise of yieldingnetic tools and more sophisticated methods for detect-
ing early ROS and discriminating individual species. the key for a new type of approach to therapy.
Finally, there is evidence to suggest that the coupling
of ROS and JNK signaling downstream of TNF-Rs is Can G. Pham, Salvatore Papa, Concetta Bubici,
Francesca Zazzeroni, and Guido Franzosobidirectional. It has been proposed that in the TNF-R1-
triggered pathway for necrosis, ROS lie downstream The Ben May Institute for Cancer Research
The University of Chicago(rather than upstream) of JNK (Ventura et al., 2004).
Thus, the molecular ordering of JNK and ROS signaling 924 East 57th Street
Chicago, Illinois 60637might differ depending upon the type of PCD response
initiated by TNF-Rs. Indeed, this represents another im-
portant issue for future investigation.
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A New Function for the Elongator
Complex: Polarization
of Rab Activity?
T
b
y
The Elongator complex was first identified through i
association with hyperphosphorylated forms of RNA i
polymerase II and was thought to have a role in tran- 1
scriptional elongation in yeast. In this issue of Molec- S
ular Cell, Rahl et al. suggest a novel function for this s
complex: regulating polarized cell-surface transport. t
tDefects in the human form of this complex result in aeurodegenerative disease, familial dysautomia (FD),
uggesting that a deficiency in neuronal polarized
rafficking is the underlying cause of FD.
he activation of the Rab GTPase Sec4 is thought to
e a key step in polarized cell surface trafficking in
east. The guanine nucleotide exchange factor Sec2p
s responsible for Sec4p activation and is itself local-
zed to sites of polarized growth (Walch-Solimena et al.,
997; Elkind et al., 2000). In order to find regulators of
ec2 function, Rahl et al. (Rahl et al., 2005) initiated a
imple screen for mutants capable of suppressing the
emperature-sensitive growth of sec2-59 cells. From
his screen, they identified a loss-of-function mutant in
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455the ELP1 gene. Previous work had identified Elp1 as a
component of a multisubunit complex termed the Elon-
gator complex. Like elp1D, loss of genes encoding
either of two other Elongator subunits, Elp2 or Elp3,
resulted in suppression of the sec2-59 mutant, consis-
tent with the idea that the proteins in the Elongator
complex function together in this pathway. Surprisingly,
Rahl et al. found that the suppression of the sec2-59
defect did not appear to be working through an effect
on transcription: There were no obvious effects on Sec2
protein levels, mutants in genes known to regulate tran-
scriptional elongation failed to suppress sec2-59, and
the elongation inhibitor 6-AU also failed to have any
effect on sec2-59. The most compelling evidence that
Elp1p (and by extension the Elongator complex) is not
suppressing through transcriptional elongation comes
from examination of the subcellular localization of GFP-
Elp1p. Elp1p had previously been shown to be primarily
localized in the cytoplasm (Pokholok et al., 2002). How-
ever, this did not eliminate the possibility that Elp1p/
Elongator transiently shuttles through the nucleus as
part of its normal intracellular intinerary. Using a clever
combination of mutants defective in nuclear export
and Elp1-GFP constructs with nuclear localization/
nuclear export signals (NLS/NES) added as controls,
Rahl et al. make a convincing case that Elp1p is present
exclusively in the cytoplasm and does not even tran-
siently reside in the nucleus. This conclusion has im-
portant implications not only for the mechanism by
which the Elongator complex functions in exocytosis,
but also for whether the complex has any direct role
in transcriptional elongation in yeast. This function had
already been questioned by several recent reports that
failed to find evidence for Elongator association with
RNA PolII on actively transcribing genes (Pokholok et
al., 2002; Krogan et al., 2002). Taken together, these
data suggest a radically different view of Elongator
function: that its primary cellular role may be directed
at cytoplasmic regulatory events. How this new view
relates to its previously characterized role in transcrip-
tional elongation remains to be resolved.
How might cytoplasmic Elongator complex work on
Rab GTPase-mediated polarized trafficking? The ge-
netic and cell biological data presented by Rahl et al.
suggest that the answer to this may be complicated inFigure 1. Two Models for Regulation of Rab
Activity by Elongator
(A) Elongator acetylation would activate a
negative regulator of Rab function, Rab GAP.
(B) Elongator acetylation would inhibit a pos-
itive regulator of Rab function, Rab GEF. The
red circles represent the GDP bound form of
the Rab, and the green triangles represent
the active GTP bound form of the Rab.that it appears that Elongator has both positive and
negative aspects of its function within the cell. The pos-
itive regulatory component comes from multiple lines
of evidence that demonstrate that Elp1p is physically
associated with the Rab exchange factor Sec2. Impor-
tantly, they find that the site of interaction in Sec2 in-
cludes the COOH-terminus, which has previously been
shown to be required for the localization of the ex-
change factor to sites of polarized growth (Elkind et al.,
2000). Consistent with this mapping, Rahl et al. find that
elp1D—or an Elp1 mutant lacking the Sec2 binding re-
gion—shows a pronounced defect in the polarization of
the Sec2-GFP. Moreover, the Elp1 mutant lacking the
Sec2p interaction domain was unable to complement
elp1D. Thus, Elp1 appears to have a positive role in
promoting the polarization of Sec2p.
On the other hand, the fact that elp1D and two other
elongator subunit mutants, elp2D and elp3D, act as re-
cessive suppressors of sec2-59 strongly suggests that
it works as a negative rather than positive regulator of
Sec2 function in the cell. This is not through relief of a
Sec2p inhibitory function unrelated to its Rab exchange
activity because elp1D was also found to suppress a
temperature-sensitive allele of SEC4, the downstream
Rab target of Sec2p. These data indicate that the Elon-
gator complex serves to downregulate the function of
the post-Golgi secretory pathway, perhaps in response
to cues that coordinate cell growth with cell-cycle pro-
gression (Kozminski et al., 2003).
A particularly interesting set of observations con-
cerns the role of acetyltransferase activity in Elongator
function in this pathway. The Elp3 subunit of Elongator
has been shown to possess acetyltransferase activity
(Wittschieben et al., 1999). Using a mutant form of Elp3
with a point mutation known to abolish acetyltransfer-
ase activity, Rahl et al. show that this form of the protein
strongly suppresses the sec2-59 mutant—demonstrat-
ing that this enzymatic activity is essential to the nega-
tive regulatory function of this complex. Identification
of the target(s) of this acetyltransferase function will be
critical to delineating the precise mechanism by which
Elongator acts in this pathway.
Possible targets for acetylation by the Elongator
complex could include a Sec4 GTPase Activating Pro-
tein (GAP) or Sec2p—the Sec4 exchange factor. In the
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456first case (Figure 1A), one would predict that the acety- P
Dlation of a Sec4 GAP would act in a stimulatory fashion,
such that loss of Elongator would result in inhibition of U
Cthe GAP and thus stabilization of Sec4-GTP. Alterna-
tively, the Sec4 exchange factor itself, Sec2p, could be
the target of Elongator regulation. In this model (Figure
1B), modification of Sec2p by Elongator would have an S
inhibitory effect on Sec2 exchange activity. In this man-
Ener, Elongator deletion would result in increased Sec4
Bexchange activity. Conceivably, the acetyltransferase
Hmay act on other components involved in polarity es-
Ktablishment and maintenance in addition to the exo-
m
cytic apparatus.
KDeficiencies in the human homolog of Elp1p, also
a
known as IKAP, are responsible for a neurodegenera-
Ktive disease called familial dysautonomia (FD). The neu-
E
ronal specificity of this defect is thought to be due to M
a tissue-specific splicing defect manifested in neurons
P
(Slaugenhaupt and Gusella, 2002). IKAP is primarily 7
found in a human-cell complex that is strikingly similar R
to the yeast Elongator complex (Hawkes et al., 2002). 8
This new work by Rahl et al. suggests a radically dif- S
ferent model for the function of Elongator in yeast, 1
which if conserved in mammalian cells, would be of W
great importance in terms of understanding the normal B
role that these proteins play in polarized trafficking, but W
also in terms of understanding the underlying defect m
Scontributing to familial dysautonomia.atrick Brennwald
epartment of Cell & Developmental Biology
niversity of North Carolina at Chapel Hill
hapel Hill, North Carolina 27516
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